Picture1.jpg
Curium Announces the Submission of its Marketing Authorization Application for [18F]-DCFPyL to the European Medicines Agency
27 juin 2022 01h00 HE | Curium
Submission follows the completion of Phase III PYTHON clinical trial of [18F]-DCFPyL for recurrent prostate cancer in Europe in May 2022Phase III PYTHON clinical trial results to be presented at the...
Picture1.jpg
Curium Confirms No Supply Challenges of 177Lu-PSMA-I&T for ECLIPSE Trial
12 mai 2022 01h05 HE | Curium
ST. LOUIS, May 12, 2022 (GLOBE NEWSWIRE) -- Curium confirmed today no supply challenges of 177Lu-PSMA-I&T for the Phase 3 ECLIPSE clinical trial (NCT05204927), evaluating Lutetium...
Picture1.jpg
Curium’s Phase 3 ECLIPSE Trial Starts Enrolling Patients
03 mai 2022 01h05 HE | Curium
ST. LOUIS, May 03, 2022 (GLOBE NEWSWIRE) -- Curium announced today it has successfully enrolled and dosed patients in the ECLIPSE Trial.  ECLIPSE is a Phase 3, multi-center, open-label, randomized...
Picture1.jpg
Curium Announces Significant Increase in Detectnet™ (copper Cu 64 dotatate injection) Production Capacity
19 avr. 2022 01h00 HE | Curium
ST. LOUIS, April 19, 2022 (GLOBE NEWSWIRE) -- Curium announced today that it will be increasing production capacity of Detectnet to accommodate the significant demand in the market. Curium will now...
Picture1.jpg
Curium Announces FDA Approval of a Generic Version of DaTscan™ (Ioflupane I 123 Injection) in the U.S.
05 avr. 2022 01h05 HE | Curium
ST. LOUIS, April 05, 2022 (GLOBE NEWSWIRE) -- Curium announced today that its generic version of DaTscan (Ioflupane I 123 Injection) was approved on March 30, 2022, by the U.S. Food and Drug...
MNPR Triangle 2.JPG
Monopar Announces Clinical and Preclinical Program Updates
15 févr. 2022 08h05 HE | Monopar Therapeutics Inc.
Validive Phase 2b/3 VOICE trial now open at 43 sites; active and enrolling in US and EU Open-label Phase 1b camsirubicin trial: early signs of clinical benefit observed WILMETTE, Ill., Feb. 15,...
22157.jpg
Global Radiopharmaceuticals Market Analysis Report 2021: Market to Reach $8.9 Billion by 2026 - COVID-19 Presents Generational Opportunity
27 janv. 2022 04h43 HE | Research and Markets
Dublin, Jan. 27, 2022 (GLOBE NEWSWIRE) -- The "Radiopharmaceuticals - Global Market Trajectory & Analytics" report has been added to ResearchAndMarkets.com's offering. Global...
Curium to become major player in the supply on non carrier added Lu-177
25 janv. 2022 00h00 HE | Curium
London, Jan. 25, 2022 (GLOBE NEWSWIRE) -- Today Curium has announced a technology license agreement granting access to ECZACIBAŞI MONROL NÜKLEER ÜRÜNLER SANAYİ VE TİCARET A.Ş non carrier added...
Picture1.jpg
Curium to become major player in the supply on non carrier added Lu-177
25 janv. 2022 00h00 HE | Curium
LONDON, Jan. 25, 2022 (GLOBE NEWSWIRE) -- Today Curium has announced a technology license agreement granting access to ECZACIBAŞI MONROL NÜKLEER ÜRÜNLER SANAYİ VE TİCARET A.Ş non carrier added...
Eckert & Ziegler’s GalliaPharm® distributed by Curium in France
01 mars 2021 19h15 HE | Curium
Berlin, Germany and Paris, France, March 01, 2021 (GLOBE NEWSWIRE) -- Eckert & Ziegler Radiopharma GmbH and Curium PET France have decided to reinforce their existing long term partnership by...